Optimization of metoprolol tartrate modified-release matrix tablet formulation using Eudragit NE as binder for metoprolol fluid bed granulation

被引:2
作者
Tomuta, Ioan [1 ]
Alecu, Cristian [2 ]
Dudas, Dana [1 ]
Leucuta, Sorin E. [1 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Dept Pharmaceut Technol & Biopharmaceut, Cluj Napoca 400023, Romania
[2] SC Laropharm Srl, Dept R&D, Bucharest 087016, Romania
关键词
Eudragit NE; extended release; fluid bed granulation; hydrophilic matrix; metoprolol;
D O I
10.4103/0973-8398.102932
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this experimental work was to investigate the possibility of obtaining hydroxypropyl methylcellulose (HPMC) hydrophilic matrix extended-release dosage forms with metoprolol by using aqueous dispersions of Eudragit NE, as binders in fluid bed granulation. To evaluate the influence of formulation variables (levels of HPMC-Methocel K100 M and Surelease E7 19010) on drug release during a period of time of 12 hours, and on the kinetic release, a full factorial experimental design with two factors and three levels was used. The formulation factors were the granulation polymer concentration and the matrix-forming polymer concentration. The obtained results have shown that the percentage of the drug released during the 12 hours is influenced both by the Methocel ratio and the Eudragit NE ratio; increasing the ratios of Eudragit and Methocel leads to the decrease of the percentage of the released drug. The influence of Eudragit NE percentage is maximum at four and six hours, but the influence of Methocel K100 M concentration is almost the same at all sampling times; all studied formulations showed a kinetic release that fitted best with the Peppas model.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 20 条
  • [1] A Design and Evaluation of Layered Matrix Tablet Formulations of Metoprolol Tartrate
    Baloglu, Esra
    Senyigit, Taner
    [J]. AAPS PHARMSCITECH, 2010, 11 (02): : 563 - 573
  • [2] Eriksson L., 2000, DESIGN EXPT PRINCIPL
  • [3] Grassi Mario, 2005, Current Drug Delivery, V2, P97, DOI 10.2174/1567201052772906
  • [4] Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration
    Nellore, RV
    Rekhi, GS
    Hussain, AS
    Tillman, LG
    Augsburger, LL
    [J]. JOURNAL OF CONTROLLED RELEASE, 1998, 50 (1-3) : 247 - 256
  • [5] Prasacu I, 2009, FARMACIA, V57, P89
  • [6] Rasul A, 2010, ACTA POL PHARM, V67, P517
  • [7] Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets
    Rekhi, GS
    Nellore, RV
    Hussain, AS
    Tillman, LG
    Malinowski, HJ
    Augsburger, LL
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 59 (03) : 327 - 342
  • [8] Shoaib M Harris, 2006, Pak J Pharm Sci, V19, P119
  • [9] Development of Sustained Release Capsules Containing "Coated Matrix Granules of Metoprolol Tartrate"
    Siddique, Sabahuddin
    Khanam, Jasmina
    Bigoniya, Papiya
    [J]. AAPS PHARMSCITECH, 2010, 11 (03): : 1306 - 1314
  • [10] Polymer blends for controlled release coatings
    Siepmann, F.
    Siepmann, J.
    Walther, M.
    MacRae, R. J.
    Bodmeier, R.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2008, 125 (01) : 1 - 15